05:32 PM EDT, 09/24/2024 (MT Newswires) -- Kairos Pharma ( KAPA ) plans to collaborate with PreCheck Health Services, a clinical laboratory specializing in genetic sequencing, to develop companion biomarkers for Kairos' ENV105 therapy targeting prostate and lung cancers.

The partnership aims to advance the "precision" of patient screening and therapy monitoring in phase 1 and 2 clinical trials of ENV105, advancing treatment by identifying patients who will benefit most, Kairos Pharma ( KAPA ) said Tuesday in a statement.

Kairos Pharma ( KAPA ) shares rose 16% in recent after-hours trading.

Price: 2.34, Change: +0.33, Percent Change: +16.42